BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 28585885)

  • 41. Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial.
    Cuzick J; Sestak I; Cella D; Fallowfield L;
    Lancet Oncol; 2008 Dec; 9(12):1143-8. PubMed ID: 18976959
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Clinical and molecular characterization of BRCA-associated breast cancer: results from the DBCG.
    Soenderstrup IMH; Laenkholm AV; Jensen MB; Eriksen JO; Gerdes AM; Hansen TVO; Kruse TA; Larsen MJ; Pedersen IS; Rossing M; Thomassen M; Ejlertsen B
    Acta Oncol; 2018 Jan; 57(1):95-101. PubMed ID: 29164974
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy.
    Nguyen PL; Taghian AG; Katz MS; Niemierko A; Abi Raad RF; Boon WL; Bellon JR; Wong JS; Smith BL; Harris JR
    J Clin Oncol; 2008 May; 26(14):2373-8. PubMed ID: 18413639
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Danish Breast Cancer Cooperative Group--DBCG: History, organization, and status of scientific achievements at 30-year anniversary.
    Blichert-Toft M; Christiansen P; Mouridsen HT
    Acta Oncol; 2008; 47(4):497-505. PubMed ID: 18465316
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Danish Breast Cancer Cooperative Group (DBCG). A description of the register of the nation-wide programme for primary breast cancer.
    Andersen KW; Mouridsen HT
    Acta Oncol; 1988; 27(6A):627-47. PubMed ID: 3064772
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human epidermal growth factor receptor-2 positivity predicts locoregional recurrence in patients with T1-T2 breast cancer.
    Cefaro GA; Genovesi D; Trignani M; DI Nicola M
    Anticancer Res; 2014 Mar; 34(3):1207-12. PubMed ID: 24596361
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Goserelin plus tamoxifen compared to chemotherapy followed by tamoxifen in premenopausal patients with early stage-, lymph node-negative breast cancer of luminal A subtype.
    Alramadhan M; Ryu JM; Rayzah M; Nam SJ; Kim SW; Yu J; Lee SK; Bae SY; Park S; Paik HJ; Lee JE
    Breast; 2016 Dec; 30():111-117. PubMed ID: 27697675
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Menopausal status does not predict Oncotype DX recurrence score.
    Carr DN; Vera N; Sun W; Lee MC; Hoover S; Fulp W; Acs G; Laronga C
    J Surg Res; 2015 Sep; 198(1):27-33. PubMed ID: 26095420
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Are there changes in characteristics and therapy of young patients with early-onset breast cancer in Germany over the last decade?
    Banz-Jansen C; Heinrichs A; Hedderich M; Waldmann A; Wedel B; Mebes I; Diedrich K; Rody A; Fischer D
    Arch Gynecol Obstet; 2013 Aug; 288(2):379-83. PubMed ID: 23407999
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Steroid receptor status and its clinicopathological correlation in post-menopausal breast cancer patients of Kumaon region of Uttarakhand.
    Shahi KS; Bhandari G; Singh A
    J Cancer Res Ther; 2011; 7(1):19-22. PubMed ID: 21546737
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Gene expression of estrogen receptor, progesterone receptor and microtubule-associated protein Tau in high-risk early breast cancer: a quest for molecular predictors of treatment benefit in the context of a Hellenic Cooperative Oncology Group trial.
    Pentheroudakis G; Kalogeras KT; Wirtz RM; Grimani I; Zografos G; Gogas H; Stropp U; Pectasides D; Skarlos D; Hennig G; Samantas E; Bafaloukos D; Papakostas P; Kalofonos HP; Pavlidis N; Fountzilas G
    Breast Cancer Res Treat; 2009 Jul; 116(1):131-43. PubMed ID: 18668363
    [TBL] [Abstract][Full Text] [Related]  

  • 52. [Local recurrence based on size after conservative surgery in breast cancer stage T1-T2. A population-based study].
    Martínez-Ramos D; Fortea-Sanchis C; Escrig-Sos J; Prats-de Puig M; Queralt-Martín R; Salvador-Sanchis JL
    Cir Cir; 2014; 82(3):252-61. PubMed ID: 25238466
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Re-evaluating adjuvant breast cancer trials: assessing hormone receptor status by immunohistochemical versus extraction assays.
    Regan MM; Viale G; Mastropasqua MG; Maiorano E; Golouh R; Carbone A; Brown B; Suurküla M; Langman G; Mazzucchelli L; Braye S; Grigolato P; Gelber RD; Castiglione-Gertsch M; Price KN; Coates AS; Goldhirsch A; Gusterson B;
    J Natl Cancer Inst; 2006 Nov; 98(21):1571-81. PubMed ID: 17077359
    [TBL] [Abstract][Full Text] [Related]  

  • 54. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer.
    Clahsen PC; van de Velde CJ; Duval C; Pallud C; Mandard AM; Delobelle-Deroide A; van den Broek L; Sahmoud TM; van de Vijver MJ
    J Clin Oncol; 1998 Feb; 16(2):470-9. PubMed ID: 9469330
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Low-dose Aspirin, Nonsteroidal Anti-inflammatory Drugs, Selective COX-2 Inhibitors and Breast Cancer Recurrence.
    Cronin-Fenton DP; Heide-Jørgensen U; Ahern TP; Lash TL; Christiansen P; Ejlertsen B; Sørensen HT
    Epidemiology; 2016 Jul; 27(4):586-93. PubMed ID: 27007644
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The Effect of Molecular Subtype and Residual Disease on Locoregional Recurrence in Breast Cancer Patients Treated with Neoadjuvant Chemotherapy and Postmastectomy Radiation.
    Yang TJ; Morrow M; Modi S; Zhang Z; Krause K; Siu C; McCormick B; Powell SN; Ho AY
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S495-501. PubMed ID: 26130454
    [TBL] [Abstract][Full Text] [Related]  

  • 57. High local recurrence risk is not associated with large survival reduction after postmastectomy radiotherapy in high-risk breast cancer: a subgroup analysis of DBCG 82 b&c.
    Kyndi M; Overgaard M; Nielsen HM; Sørensen FB; Knudsen H; Overgaard J
    Radiother Oncol; 2009 Jan; 90(1):74-9. PubMed ID: 18471914
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Breast Tumor Prognostic Characteristics and Biennial vs Annual Mammography, Age, and Menopausal Status.
    Miglioretti DL; Zhu W; Kerlikowske K; Sprague BL; Onega T; Buist DS; Henderson LM; Smith RA;
    JAMA Oncol; 2015 Nov; 1(8):1069-77. PubMed ID: 26501844
    [TBL] [Abstract][Full Text] [Related]  

  • 59. HER2 status in hormone receptor positive premenopausal primary breast cancer adds prognostic, but not tamoxifen treatment predictive, information.
    Rydén L; Landberg G; Stål O; Nordenskjöld B; Fernö M; Bendahl PO
    Breast Cancer Res Treat; 2008 May; 109(2):351-7. PubMed ID: 17636399
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Does administration of chemotherapy before radiotherapy in breast cancer patients treated with conservative surgery negatively impact local control?
    Leonard CE; Wood ME; Zhen B; Rankin J; Waitz DA; Norton L; Howell K; Sedlacek S
    J Clin Oncol; 1995 Dec; 13(12):2906-15. PubMed ID: 8523054
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.